CU22640A1 - Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas - Google Patents

Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas

Info

Publication number
CU22640A1
CU22640A1 CU1996032A CU1996032A CU22640A1 CU 22640 A1 CU22640 A1 CU 22640A1 CU 1996032 A CU1996032 A CU 1996032A CU 1996032 A CU1996032 A CU 1996032A CU 22640 A1 CU22640 A1 CU 22640A1
Authority
CU
Cuba
Prior art keywords
diagnosis
monoclonal antibodies
recurrences
metastases
pharmaceutical composition
Prior art date
Application number
CU1996032A
Other languages
English (en)
Inventor
Mesa Nelson Victor Rodriguez
Gonzalez Juan Perfecto Oliva
Morales Alejo Antonio Morales
Escobar Normando Enrique Iznaga
Zuzarte Mayra Ramos
Gandolff Gilda Nunez
Bravo Blanca Rosa Tormo
Lopez Ana Maria Vazquez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1996032A priority Critical patent/CU22640A1/es
Priority to ARP970100979A priority patent/AR006195A1/es
Priority to PCT/CU1997/000002 priority patent/WO1997033916A1/es
Publication of CU22640A1 publication Critical patent/CU22640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con la rama de la Medicina Nuclear y en particular proporciona un kit y una composición farmaceútica que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos para el diagnóstico y la terapia de neoplasias malignas. De acuerdo con lo planteado, un objeto de esta invención es proporcionar una composición farmacéutica constituida por un "kit" que contiene anticuerpos monoclonales que reconocen el antígeno ior C2 y un ligando débil con el agente reductor Sn 2+para realizar la transferencia del Tc-99m, Re-186, Re-188 y sus similares, útil para el diagnóstico por inmunogammagrafía y radioinmunoterapia de tumores colorrectales, metástasis y recidivas. Se proporciona además un método para la determinación de la actividad biológica de los anticuerpos monoclonales reducidos por medio del cálculo de la constante de afinidad a través de un ensayo ELISA competitivo. La esencia de la invención consiste en el radiomarcaje de anticuerpos monoclonales que reconocen al antígeno ior C2, epitopes similares o idénticos a éste y fragmentos de éstos, con isótopos radioactivos tales como el tecnecio-99m (Tc-99m), el renio-186 (Re-186), el renio-188 (Re-188) y sus análogos, y sus usos en composiciones farmacéuticas para el diagnóstico por inmunogammagrafía y/o radioinmunoterapia de tumores colorrectales, metástasis y recidivas. Así mismo, por medio de los métodos directos de marcaje se llega a la conformación de un kit para utilizarlo en el diagnóstico y/o tratamiento de estos tumores.
CU1996032A 1996-03-12 1996-03-12 Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas CU22640A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU1996032A CU22640A1 (es) 1996-03-12 1996-03-12 Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas
ARP970100979A AR006195A1 (es) 1996-03-12 1997-03-12 Anticuerpo monoclonales ior c5 para el diagnostico y tratamiento de tumores colorrectales
PCT/CU1997/000002 WO1997033916A1 (es) 1996-03-12 1997-03-12 Anticuerpos monoclonales ior c5 para el diagnostico y tratamiento de tumores colorrectales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1996032A CU22640A1 (es) 1996-03-12 1996-03-12 Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas

Publications (1)

Publication Number Publication Date
CU22640A1 true CU22640A1 (es) 2000-12-22

Family

ID=46093344

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1996032A CU22640A1 (es) 1996-03-12 1996-03-12 Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas

Country Status (3)

Country Link
AR (1) AR006195A1 (es)
CU (1) CU22640A1 (es)
WO (1) WO1997033916A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein

Also Published As

Publication number Publication date
AR006195A1 (es) 1999-08-11
WO1997033916A1 (es) 1997-09-18

Similar Documents

Publication Publication Date Title
Khaw et al. Technetium-99m labeling of antibodies to cardiac myosin Fab and to human fibrinogen
Velikyan et al. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity
Kukis et al. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates
Thakur et al. Technetium-99m labeled monoclonal antibodies: evaluation of reducing agents
Glaser et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography
DK0486622T3 (da) Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
Price et al. A comparative evaluation of the chelators H4octapa and CHX-A ″-DTPA with the therapeutic radiometal 90Y
BR1100906A (pt) Composição que é um agente de formação de imagens cintilográficas para mapeamento de sìtios de inflamação em um mamìfero, produto de manufatura compreendendo um kit de elaboração de uma preparação radiofarmacêutica, processo de preparação do reagente, e, composição de matéria
Koumarianou et al. 44Sc-DOTA-BN [2-14] NH2 in comparison to 68Ga-DOTA-BN [2-14] NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
KR920700690A (ko) α-입자 방출을 이용하는 방사선 면역치료제
YU61701A (sh) Postupak i kit za efikasno radioobeležavanje proteina sa terapeutskim radioizotopom
Tolmachev et al. Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T
FR2297034A1 (fr) Composition pour la localisation d'isotopes radioactifs en medecine
Uccelli et al. Monoclonal Antibodies Radiolabeling with Rhenium‐188 for Radioimmunotherapy
Iznaga-Escobar Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors—a review of radiolabeling characteristics, quality control and in vitro stability studies
Zamora et al. Preparation of 188Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy
Kwok et al. Optimization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model
BR9809785A (pt) Composto de ligação de receptor de calcitonina, reagente, agente de formação de imagem cintigráfica, composição, agente radio-terapêutico, complexo, kit para preparar uma preparação radio-farmacêutica, processos para rotular o reagente, para fabricar o reagente, e, uso do reagente
Sundin et al. High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T
Hnatowich Label stability in serum of four radionuclides on DTPA-coupled antibodies—an evaluation
Kameswaran et al. 131I-Nimotuzumab–A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR
Lindegren et al. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl) benzoate as an intermediate
De Decker et al. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia
Pimm et al. Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies

Legal Events

Date Code Title Description
MK Ceased due to expiration of term